Supply Chain Archives
12/19/2025
Expert Q&A: Is Standardization the Bottleneck or Breakthrough to Building Scalable and Cost-Effective CGT Programs?
Cell and gene therapy (CGT) companies are under constant pressure to do more while hitting milestones earlier. Demonstrate manufacturability. Ensure regulatory readiness. Design for scalability and patient access. And do all of this with more constrained resources and increasingly aggressive timelines. Building on our recent panel discussion, we gathered extended perspectives from Dr. Don Fink (Dark Horse Consulting Group), Audrey Greenberg (Mayo Venture Partners), Dr. Dominic Clarke (Cryoport Systems), and Kurtis Carlisle (Cabaletta Bio).
12/17/2025
2025 Year in Review: Turning Standards and Resilience into Outcomes
If you work within the advanced therapy ecosystem, you already know the story of 2025 from an industry standpoint, where science continued accelerating while funding and commercialization hinged on whether the supporting systems could keep up. For Cryoport Systems, that reality was a catalyst. This year, we raised the bar yet again and demonstrated how having the right strategic partnership behind your end-to-end supply chain can turn logistics into leverage, can transform compliance into confidence, and can spin scale into speed.
07/22/2025
What’s Next for the CGT Industry? Mid-Year Check-In from the Leadership Team
We’re halfway through 2025, and the cell and gene therapy (CGT) landscape stands at a crossroads. Innovation continues to advance, yet the infrastructure required to support commercialization remains under pressure. To assess the current state of the industry and what’s ahead, Cryoport Systems gathered candid insights from our internal leaders across functions, from product development and commercial strategy to operations and client engagement.
06/04/2025
Engineering for Impact: A Conversation with Mike Dybicz on the HV3 and Safepak Systems
When it comes to cell and gene therapy (CGT) logistics, innovation is about more than improving efficiency, it’s about safeguarding a patient’s only chance at treatment. We sat down with Mike Dybicz, Senior Vice President & Chief Product Development Officer, to discuss how Cryoport Systems is reshaping the future of CGT logistics with innovative products such as Cryoport Express® Cryogenic HV3 Shipping System and Safepak® System 1800, designed specifically to reduce risk, increase reliability, and ultimately improve patient outcomes.
04/22/2025
Advancing Standardization in Cell and Gene Therapy Supply Chains
The future of cell and gene therapy depends not only on scientific advancements but also on the efficiency and reliability of its supply chain. In a recent panel discussion at Advanced Therapies Congress in London, industry experts explored the critical need for standardization, the challenges in achieving it, and the opportunities to improve logistics, manufacturing, and delivery systems.
04/18/2025
Transforming Patient Access to CGT: Q&A with Aruna Mor
Aruna Mor, Chief Commercial Officer at Cryoport Systems, recently delivered a powerful keynote at Advanced Therapies Congress in London, shedding light on the complexities of patient access and the critical steps needed to overcome these barriers. We sat down with her to delve deeper into some of the key themes of her keynote, exploring the intersection of science, logistics, supply chain, regulation, and collaboration that will determine the future of Cell and Gene Therapy (CGT).
04/14/2025
Enabling the Outcome Through Enhancing Patient Accessibility
Cell and Gene Therapy (CGT) has emerged as one of the most transformative areas in modern medicine, shaping the future of healthcare and changing the face of next-generation therapeutic approaches. Yet, despite the continued scientific progress, a critical challenge persists in ensuring these therapies are accessible to the patients who need them most. This challenge was the focus of the keynote address at the Advanced Therapies Congress in London, delivered by Aruna Mor, Chief Commercial Officer at Cryoport Systems, where she spoke about to the state of patient access within the field of advanced therapeutics.
02/12/2025
Ensuring Patient Impact in Advanced Therapy Logistics: A Conversation with Cryoport Systems’ Experts
The logistics behind advanced therapies aren’t just about moving shipments from point A to point B, they’re about protecting the integrity of life-saving treatments and ensuring that patients receive them without compromise. Following their discussion at Advanced Therapies Week 2025, we sat down with Aruna Mor, Chief Commercial Officer, and Mike Dybicz, Senior Vice President & Chief Product Development Officer, to dive deeper into how Cryoport Systems prioritizes patient impact at every step of the supply chain.
02/06/2025
